What AbbVie's Quarter ended Sep 30, 2026 10-Q says: 4 signals
AbbVie filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses acquisition completed, AI investment and litigation material.
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.- Filed
- Nov 3, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 13
Source: Autobound Signal API · 112 signals tracked for AbbVie · updated
10-Q · latest 10
What AbbVie's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
AbbVie announced an investment in 2026 to build a pharmaceutical manufacturing campus in North Carolina that integrates advanced manufacturing and laboratory technologies with artificial intelligence.
artificial intelligenceadvanced manufacturing and laboratory technologies
AbbVie paid $10.6 billion primarily for Apogee acquisition and closed Arizona device facility
AbbVie made investing cash payments of $10.6 billion primarily related to the acquisition of Apogee and closed an agreement to acquire an Arizona device manufacturing facility in July 2026.
$10.6B
payments made for acquisitions of businesses, net of cash acquired primarily related to the acquisition of Apogee
District Court vacates CMS selection of Botox for Medicare Drug Price Negotiation Program
On October 29, 2026, the United States District Court for the District of Columbia vacated CMS's selection of Botox for price negotiation and enjoined CMS from publishing a maximum fair price.
Imbruvica U.S. revenues decrease 33% driven by unfavorable pricing and lower demand
AbbVie reported a 33% decline in U.S. Imbruvica revenues for the quarter and 26% globally, citing unfavorable pricing and decreased demand in the United States.
-26%
global Imbruvica revenue decrease for the three months ended September 30, 2026
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
AbbVie announced an investment in 2026 to build a pharmaceutical manufacturing campus in North Carolina that integrates laboratory technologies and artificial intelligence to support immunology, neuroscience, and oncology medicine production.
advanced manufacturing and laboratory technologiesartificial intelligence
AbbVie Enters $10.0 Billion Credit Term Loan to Finance Proposed Acquisition of Apogee
AbbVie entered into a $10.0 billion 364-day senior unsecured term loan facility subsequent to June 30, 2026, in connection with its proposed acquisition of Apogee.
$10B
senior unsecured term loan facility to finance proposed acquisition of Apogee
AbbVie issues $8.0 billion in senior notes and enters $10.0 billion term loan agreement
AbbVie issued $8.0 billion aggregate principal of unsecured senior notes and repaid $4.0 billion in existing borrowings during the first six months of 2026.
$8B
issuance of unsecured senior notes
Botox selected for Medicare price negotiation under Inflation Reduction Act starting in 2028
CMS selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028 under the Inflation Reduction Act of 2022.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 5 signals
AbbVie announced new North Carolina campus and two Illinois manufacturing facilities
AbbVie announced capital investments to build an advanced manufacturing and laboratory campus integrating AI in North Carolina, add two manufacturing facilities in Illinois, and acquire a device facility in Arizona.
artificial intelligence
AbbVie announced an investment in 2026 to build a pharmaceutical manufacturing campus in North Carolina that integrates artificial intelligence with advanced manufacturing and laboratory technologies.
artificial intelligence
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
AbbVie earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Net revenues reach $17.4B, up 10.5% operational growthAbbVie delivered $17.4 billion in Q3 2026 total net revenues, beating guidance by $200 million and delivering 10.5% operational growth. Nine key commercial products delivered double-digit growth, driving strong operating cash flow and high vendor evaluation capacity. | |
| IRA price negotiation and 340B discounts pressure drug revenuesImbruvica revenues dropped 26.1% due to Medicare IRA pricing and competitive pressure, while broader 340B hospital program growth creates persistent pricing headwinds. AbbVie is participating in a 340B rebate pilot for Imbruvica, Linzess, and Vraylar to curb perceived program abuse. | |
| Partnership with Genmab advances Epkinly in frontline lymphomaAbbVie is collaborating with Genmab on Epkinly, booking profit share in the U.S., Puerto Rico, and Japan. Regulatory submissions for frontline DLBCL are planned for early next year following positive Phase III results reducing risk of disease progression or death by 51%. | |
| Expansion into dermatology sales forces for vitiligo and alopeciaAbbVie is building out dedicated dermatology commercial sales forces globally to support anticipated U.S. approvals and European launches for Rinvoq in vitiligo and alopecia areata. Management projects these two new indications will generate nearly $2 billion in peak sales. | |
| Biosimilar competition reduces global Humira sales by 30.6%Global Humira sales fell 30.6% operationally to $683 million as biosimilar erosion continues to impact market share. The ongoing erosion reinforces the company's transition to newer immunology assets Skyrizi and Rinvoq. | |
| Aesthetics segment pressured by economic uncertainty and dermal filler headwindsGlobal aesthetics revenue dropped 1.8% to nearly $1.2 billion, driven by an 11.8% operational decline in Juvéderm sales. Management cited lower consumer confidence and macro pressures on elective procedures, though early signs of stabilization are emerging. |
Signal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about AbbVie 10-Q
When did AbbVie file its latest 10-Q?
What did AbbVie disclose in its latest 10-Q?
What did AbbVie say on its recent earnings calls?
Where can I read AbbVie's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .